Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SelectQuote, Inc. Reports Second Quarter 2024 Results

SLQT

Second Quarter of Fiscal Year 2024 – Consolidated Earnings Highlights

  • Revenue of $405.4 million
  • Net income of $19.4 million
  • Adjusted EBITDA* of $67.4 million

Raising Fiscal Year 2024 Guidance Ranges:

  • Revenue expected in a range of $1.23 billion to $1.3 billion vs prior range of $1.05 billion to $1.2 billion
  • Net loss expected in a range of $45 million to $22 million vs prior range of $50 million to $22 million
  • Adjusted EBITDA* expected in a range of $90 million to $105 million vs prior range of $80 million to $105 million

Second Quarter of Fiscal Year 2024 – Segment Highlights

Senior

  • Revenue of $247.5 million
  • Adjusted EBITDA* of $78.7 million
  • Approved Medicare Advantage policies of 234,576

Healthcare Services

  • Revenue of $111.7 million
  • Adjusted EBITDA* of $3.0 million
  • Over 62,000 SelectRx members

Life

  • Revenue of $37.4 million
  • Adjusted EBITDA* of $4.6 million

Auto & Home

  • Revenue of $10.5 million
  • Adjusted EBITDA* of $4.7 million

SelectQuote, Inc. (NYSE: SLQT) reported consolidated revenue for the second quarter of fiscal year 2024 of $405.4 million, compared to consolidated revenue for the second quarter of fiscal year 2023 of $319.2 million. Consolidated net income for the second quarter of fiscal year 2024 was $19.4 million, compared to consolidated net income for the second quarter of fiscal year 2023 of $22.5 million. Finally, consolidated Adjusted EBITDA* for the second quarter of fiscal year 2024 was $67.4 million, compared to consolidated Adjusted EBITDA* for the second quarter of fiscal year 2023 of $63.6 million.

Chief Executive Officer Tim Danker stated, “The second quarter marked SelectQuote’s eighth consecutive quarter of performance ahead of expectations, and we remain confident that our strategy to prioritize predictable and cash efficient growth will continue to generate value for both our customers and shareholders. We are also pleased with our progress on operating cash flow and now anticipate that SelectQuote will approach positive free cash flow in fiscal 2024.”

“SelectQuote drove strong results throughout the annual enrollment period for Medicare Advantage where our Senior business grew revenues by double digits, and our second quarter Adjusted EBITDA margin of 32% remains attractive. These strong Senior operating results were a function of higher tenured agent productivity and solid policyholder persistency, which we expect to benefit SelectQuote in the open enrollment period as well.”

“Additionally, Healthcare Services, and our SelectRx business specifically, drove substantial growth in excess of our original forecast. As of the end of the second quarter, SelectRx members have surpassed 62,000, which is in excess of our original expectation for the full year. More importantly, the business was again Adjusted EBITDA profitable.”

Mr. Danker continued, “We are pleased to increase our fiscal year 2024 outlook based on the strength of both businesses year-to-date.”

Segment Results

We currently report on four segments: 1) Senior, 2) Healthcare Services, 3) Life, and 4) Auto & Home. The performance measures of the segments include total revenue, Adjusted EBITDA,* and Adjusted EBITDA Margin.* Costs of revenue, cost of goods sold-pharmacy revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount. Adjusted EBITDA is calculated as total revenue for the applicable segment less direct and allocated costs of revenue, cost of goods sold, marketing and advertising, technical development, and selling, general, and administrative operating costs and expenses, excluding depreciation and amortization expense; gain or loss on disposal of property, equipment, and software; share-based compensation expense; and non-recurring expenses such as severance payments and transaction costs.

Senior

Financial Results

The following table provides the financial results for the Senior segment for the periods presented:

Three Months Ended December 31,

Six Months Ended December 31,

(in thousands)

2023

2022

% Change

2023

2022

% Change

Revenue

$

247,529

$

223,826

11

%

$

337,445

$

301,340

12

%

Adjusted EBITDA*

78,713

83,617

(6

)%

77,376

79,766

(3

)%

Adjusted EBITDA Margin*

32

%

37

%

23

%

26

%

Operating Metrics

Submitted Policies

Submitted policies are counted when an individual completes an application with our licensed agent and provides authorization to the agent to submit the application to the insurance carrier partner. The applicant may have additional actions to take before the application will be reviewed by the insurance carrier.

The following table shows the number of submitted policies for the periods presented:

Three Months Ended December 31,

Six Months Ended December 31,

2023

2022

% Change

2023

2022

% Change

Medicare Advantage

271,712

251,847

8

%

376,244

341,875

10

%

Medicare Supplement

1,203

1,565

(23

)%

1,684

2,230

(24

)%

Dental, Vision and Hearing

19,808

22,004

(10

)%

32,304

38,338

(16

)%

Prescription Drug Plan

1,720

1,302

32

%

2,031

1,666

22

%

Other

1,318

1,512

(13

)%

2,950

3,538

(17

)%

Total

295,761

278,230

6

%

415,213

387,647

7

%

*See “Non-GAAP Financial Measures” below.

Approved Policies

Approved policies represents the number of submitted policies that were approved by our insurance carrier partners for the identified product during the indicated period. Not all approved policies will go in force.

The following table shows the number of approved policies for the periods presented:

Three Months Ended December 31,

Six Months Ended December 31,

2023

2022

% Change

2023

2022

% Change

Medicare Advantage

234,576

218,837

7

%

332,257

302,010

10

%

Medicare Supplement

773

1,127

(31

)%

1,133

1,627

(30

)%

Dental, Vision and Hearing

16,903

18,697

(10

)%

27,432

30,972

(11

)%

Prescription Drug Plan

1,316

883

49

%

1,570

1,273

23

%

Other

993

1,241

(20

)%

2,045

2,903

(30

)%

Total

254,561

240,785

6

%

364,437

338,785

8

%

Lifetime Value of Commissions per Approved Policy

Lifetime value of commissions per approved policy represents commissions estimated to be collected over the estimated life of an approved policy based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints. The lifetime value of commissions per approved policy is equal to the sum of the commission revenue due upon the initial sale of a policy, and when applicable, an estimate of future renewal commissions.

The following table shows the lifetime value of commissions per approved policy for the periods presented:

Three Months Ended December 31,

Six Months Ended December 31,

(dollars per policy):

2023

2022

% Change

2023

2022

% Change

Medicare Advantage

$

934

$

870

7

%

$

883

$

845

4

%

Medicare Supplement

1,045

994

5

%

1,044

1,037

1

%

Dental, Vision and Hearing

69

116

(41

)%

99

97

2

%

Prescription Drug Plan

230

212

8

%

237

219

8

%

Other

(50

)

115

(143

)%

(18

)

91

(120

)%

Healthcare Services

Financial Results

The following table provides the financial results for the Healthcare Services segment for the periods presented:

Three Months Ended December 31,

Six Months Ended December 31,

(in thousands)

2023

2022

% Change

2023

2022

% Change

Revenue

$

111,710

$

55,480

101

%

$

209,078

$

98,546

112

%

Adjusted EBITDA*

2,981

(9,301

)

132

%

5,304

(21,089

)

125

%

Adjusted EBITDA Margin*

3

%

(17

)%

3

%

(21

)%

*See “Non-GAAP Financial Measures” below.

Operating Metrics

Total Members

The total number of SelectRx members represents the amount of customers to which an order has been shipped, as this is the primary key driver of revenue for Healthcare Services.

The following table shows the total number of SelectRx members for the date presented:

December 31, 2023

December 31, 2022

Total SelectRx Members

62,623

39,308

Prescriptions Per Day

Prescriptions per day represents the total prescriptions shipped per business day, as this is a primary key driver of revenue for Healthcare Services.

The following table shows the prescriptions shipped per day for the periods presented:

Three Months Ended December 31,

Six Months Ended December 31,

2023

2022

2023

2022

Prescriptions Per Day

17,010

9,652

16,244

8,754

Combined Senior and Healthcare Services - Consumer Per Unit Economics

The opportunity to leverage our existing database and distribution model to improve access to healthcare services for our consumers has created a need for us to review our key metrics related to our per unit economics. As we think about the revenue and expenses for Healthcare Services, we note that they are derived from the marketing acquisition costs associated with the sale of an MA or MS policy, some of which costs are allocated directly to Healthcare Services, and therefore determined that our per unit economics measure should include components from both Senior and Healthcare Services. See details of revenue and expense items included in the calculation below.

Combined Senior and Healthcare Services consumer per unit economics represents total MA and MS commissions; other product commissions; other revenues, including revenues from Healthcare Services; and operating expenses associated with Senior and Healthcare Services, each shown per number of approved MA and MS policies over a given time period. Management assesses the business on a per-unit basis to help ensure that the revenue opportunity associated with a successful policy sale is attractive relative to the marketing acquisition cost. Because not all acquired leads result in a successful policy sale, all per-policy metrics are based on approved policies, which is the measure that triggers revenue recognition.

The MA and MS commission per MA/MS policy represents the LTV for policies sold in the period. Other commission per MA/MS policy represents the LTV for other products sold in the period, including DVH prescription drug plan, and other products, which management views as additional commission revenue on our agents’ core function of MA/MS policy sales. Pharmacy revenue per MA/MS policy represents revenue from SelectRx, and other revenue per MA/MS policy represents revenue from Population Health, production bonuses, marketing development funds, lead generation revenue, and adjustments from the Company’s reassessment of its cohorts’ transaction prices. Total operating expenses per MA/MS policy represents all of the operating expenses within Senior and Healthcare Services. The revenue to customer acquisition cost (“CAC”) multiple represents total revenue as a multiple of total marketing acquisition costs, which represents the direct costs of acquiring leads. These costs are included in marketing and advertising expense within the total operating expenses per MA/MS policy.

The following table shows combined Senior and Healthcare Services consumer per unit economics for the periods presented. Based on the seasonality of Senior and the fluctuations between quarters, we believe that the most relevant view of per unit economics is on a rolling 12-month basis. All per MA/MS policy metrics below are based on the sum of approved MA/MS policies, as both products have similar commission profiles.

Twelve Months Ended December 31,

(dollars per approved policy):

2023

2022

Medicare Advantage and Medicare Supplement approved policies

609,939

617,687

Medicare Advantage and Medicare Supplement commission per MA/MS policy

$

896

$

880

Other commission per MA/MS policy

11

19

Pharmacy revenue per MA/MS policy

575

225

Other revenue per MA/MS policy

140

62

Total revenue per MA/MS policy

1,622

1,186

Total operating expenses per MA/MS policy

(1,365

)

(1,111

)

Adjusted EBITDA per MA/MS policy (1)

257

75

Adjusted EBITDA Margin per MA/MS policy (1)

16

%

6

%

Revenue/CAC multiple

4.2X

3.0X

(1) These financial measures are not calculated in accordance with GAAP. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures” for information regarding our use of these non-GAAP financial measures and a reconciliation of such measures to their nearest comparable financial measures calculated and presented in accordance with GAAP.

Total revenue per MA/MS policy increased 37% for the twelve months ended December 31, 2023, compared to the twelve months ended December 31, 2022, primarily due to the increase in pharmacy revenue. Total operating expenses per MA/MS policy increased 23% for the twelve months ended December 31, 2023, compared to the twelve months ended December 31, 2022, driven by a 100% increase in operating expenses related to SelectRx due to the growth of the business, offset by a 3% decrease in other operating expenses driven by a decrease in marketing and advertising costs for the second half of fiscal year 2023 compared to the second half of fiscal year 2022.

Life

Financial Results

The following table provides the financial results for the Life segment for the periods presented:

Three Months Ended December 31,

Six Months Ended December 31,

(in thousands)

2023

2022

% Change

2023

2022

% Change

Revenue

$

37,367

$

33,995

10

%

$

75,170

$

70,830

6

%

Adjusted EBITDA*

4,569

5,843

(22

)%

9,808

11,068

(11

)%

Adjusted EBITDA Margin*

12

%

17

%

13

%

16

%

Operating Metrics

Life premium represents the total premium value for all policies that were approved by the relevant insurance carrier partner and for which the policy document was sent to the policyholder and payment information was received by the relevant insurance carrier partner during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Life segment.

*See “Non-GAAP Financial Measures” below.

The following table shows term and final expense premiums for the periods presented:

Three Months Ended December 31,

Six Months Ended December 31,

(in thousands)

2023

2022

% Change

2023

2022

% Change

Term Premiums

$

17,398

$

15,824

10

%

$

35,588

$

30,922

15

%

Final Expense Premiums

19,388

17,093

13

%

39,087

39,457

(1

)%

Total

$

36,786

$

32,917

12

%

74,675

70,379

6

%

Auto & Home

Financial Results

The following table provides the financial results for the Auto & Home segment for the periods presented:

Three Months Ended December 31,

Six Months Ended December 31,

(in thousands)

2023

2022

% Change

2023

2022

% Change

Revenue

$

10,487

$

7,808

34

%

$

19,515

$

14,890

31

%

Adjusted EBITDA*

4,725

2,284

107

%

8,045

4,725

70

%

Adjusted EBITDA Margin*

45

%

29

%

41

%

32

%

Operating Metrics

Auto & Home premium represents the total premium value of all new policies that were approved by our insurance carrier partners during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Auto & Home segment.

The following table shows premiums for the periods presented:

Three Months Ended December 31,

Six Months Ended December 31,

(in thousands):

2023

2022

% Change

2023

2022

% Change

Premiums

$

14,689

$

12,080

22

%

$

28,566

$

23,628

21

%

*See “Non-GAAP Financial Measures” below.

Earnings Conference Call

SelectQuote, Inc. will host a conference call with the investment community today, Wednesday, February 7, 2024, beginning at 8:30 a.m. ET. To register for this conference call, please use this link: https://www.netroadshow.com/events/login?show=3bad4d79&confId=59966. After registering, a confirmation will be sent via email, including dial-in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call we suggest registering at least 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website https://ir.selectquote.com/investor-home/default.aspx.

Non-GAAP Financial Measures

This release includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this release Adjusted EBITDA and Adjusted EBITDA Margin, which are non-GAAP financial measures. These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly titled measures presented by other companies. We define Adjusted EBITDA as income (loss) before interest expense, income tax expense (benefit), depreciation and amortization, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure is net income (loss). We define Adjusted EBITDA Margin as Adjusted EBITDA divided by revenue. The most directly comparable GAAP measure is net income margin. We monitor and have presented in this release Adjusted EBITDA and Adjusted EBITDA Margin because they are key measures used by our management and Board of Directors to understand and evaluate our operating performance, to establish budgets and to develop operational goals for managing our business. In particular, we believe that excluding the impact of these expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance.

We believe that these non-GAAP financial measures help identify underlying trends in our business that could otherwise be masked by the effect of the expenses that we exclude in the calculations of these non-GAAP financial measures. Accordingly, we believe these financial measures provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects. Reconciliations of the differences between the non-GAAP financial measures included herein and their most directly comparable GAAP financial measures are set forth below beginning on page 12.

Forward Looking Statements

This release contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as “may,” “should,” “could,” “predict,” “potential,” “believe,” “will likely result,” “expect,” “continue,” “will,” “anticipate,” “seek,” “estimate,” “intend,” “plan,” “projection,” “would” and “outlook,” or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.

There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: the impacts of the COVID-19 pandemic and any other public health events, our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, including exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the U.S. health insurance system; our dependence on revenue from carriers in our senior segment and downturns in the senior health as well as life, automotive and home insurance industries; our ability to develop new offerings and penetrate new vertical markets; risks from third-party products; failure to enroll individuals during the Medicare annual enrollment period; our ability to attract, integrate and retain qualified personnel; our dependence on lead providers and ability to compete for leads; failure to obtain and/or convert sales leads to actual sales of insurance policies; access to data from consumers and insurance carriers; accuracy of information provided from and to consumers during the insurance shopping process; cost-effective advertisement through internet search engines; ability to contact consumers and market products by telephone; global economic conditions, including inflation; disruption to operations as a result of future acquisitions; significant estimates and assumptions in the preparation of our financial statements; impairment of goodwill; potential litigation and other legal proceedings or inquiries; our existing and future indebtedness; our ability to maintain compliance with our debt covenants and meet our scheduled repayment obligations under out debt arrangement; our ability to access to additional capital on acceptable terms; failure to protect our intellectual property and our brand; fluctuations in our financial results caused by seasonality; accuracy and timeliness of commissions reports from insurance carriers; timing of insurance carriers’ approval and payment practices; factors that impact our estimate of the constrained lifetime value of commissions per policyholder; changes in accounting rules, tax legislation and other legislation; disruptions or failures of our technological infrastructure and platform; failure to maintain relationships with third-party service providers; cybersecurity breaches or other attacks involving our systems or those of our insurance carrier partners or third-party service providers; our ability to protect consumer information and other data; failure to market and sell Medicare plans effectively or in compliance with laws; and other factors related to our pharmacy business, including manufacturing or supply chain disruptions, access to and demand for prescription drugs, and regulatory changes or other industry developments that may affect our pharmacy operations. For a further discussion of these and other risk factors that could impact our future results and performance, see the section entitled “Risk Factors” in the most recent Annual Report on Form 10-K and subsequent periodic reports filed by us with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

About SelectQuote:

Founded in 1985, SelectQuote (NYSE: SLQT) provides solutions that help consumers protect their most valuable assets: their families, health, and property. The company pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote’s success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads.

With an ecosystem offering high touchpoints for consumers across insurance, medicare, pharmacy, and value-based care, the company now has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, and Population Health which proactively connects consumers with a wide breadth of healthcare services supporting their needs.

Source: SelectQuote, Inc.

SELECTQUOTE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands)

December 31, 2023

June 30, 2023

ASSETS

CURRENT ASSETS:

Cash and cash equivalents

$

10,849

$

83,156

Accounts receivable, net of allowances of $4.7 million and $2.7 million, respectively

142,590

154,565

Commissions receivable-current

207,279

111,148

Other current assets

27,100

14,355

Total current assets

387,818

363,224

COMMISSIONS RECEIVABLE—Net

747,079

729,350

PROPERTY AND EQUIPMENT—Net

23,389

27,452

SOFTWARE—Net

14,428

14,740

OPERATING LEASE RIGHT-OF-USE ASSETS

22,035

23,563

INTANGIBLE ASSETS—Net

8,684

10,200

GOODWILL

29,136

29,136

OTHER ASSETS

3,350

21,586

TOTAL ASSETS

$

1,235,919

$

1,219,251

LIABILITIES AND SHAREHOLDERS’ EQUITY

CURRENT LIABILITIES:

Accounts payable

$

57,392

$

27,577

Accrued expenses

16,698

16,993

Accrued compensation and benefits

48,680

49,966

Operating lease liabilities—current

5,133

5,175

Current portion of long-term debt

42,766

33,883

Contract liabilities

9,092

1,691

Other current liabilities

4,211

1,972

Total current liabilities

183,972

137,257

LONG-TERM DEBT, NET—less current portion

650,772

664,625

DEFERRED INCOME TAXES

36,668

39,581

OPERATING LEASE LIABILITIES

25,245

27,892

OTHER LIABILITIES

2,745

2,926

Total liabilities

899,402

872,281

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS’ EQUITY:

Common stock, $0.01 par value

1,690

1,669

Additional paid-in capital

573,883

567,266

Accumulated deficit

(247,303

)

(235,644

)

Accumulated other comprehensive income

8,247

13,679

Total shareholders’ equity

336,517

346,970

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

$

1,235,919

$

1,219,251

SELECTQUOTE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited)

(In thousands)

Three Months Ended December 31,

Six Months Ended December 31,

2023

2022

2023

2022

REVENUE:

Commission

$

263,225

$

230,033

$

380,981

336,368

Pharmacy

108,795

51,601

203,583

92,694

Other

33,418

37,554

53,603

52,610

Total revenue

405,438

319,188

638,167

481,672

OPERATING COSTS AND EXPENSES:

Cost of revenue

97,424

91,477

169,935

156,641

Cost of goods sold—pharmacy revenue

94,180

50,096

178,188

92,450

Marketing and advertising

117,078

89,925

179,400

147,519

Selling, general, and administrative

33,412

28,412

62,078

59,118

Technical development

8,050

6,245

15,687

12,427

Total operating costs and expenses

350,144

266,155

605,288

468,155

INCOME FROM OPERATIONS

55,294

53,033

32,879

13,517

INTEREST EXPENSE, NET

(24,415

)

(21,044

)

(45,811

)

(37,780

)

OTHER INCOME (EXPENSE), NET

(70

)

(39

)

88

INCOME (LOSS) BEFORE INCOME TAX EXPENSE (BENEFIT)

30,879

31,919

(12,971

)

(24,175

)

INCOME TAX EXPENSE (BENEFIT)

11,487

9,405

(1,312

)

(4,205

)

NET INCOME (LOSS)

$

19,392

$

22,514

$

(11,659

)

(19,970

)

NET INCOME (LOSS) PER SHARE:

Basic

$

0.12

$

0.14

$

(0.07

)

$

(0.12

)

Diluted

$

0.11

$

0.14

$

(0.07

)

$

(0.12

)

WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS:

Basic

168,349

166,486

167,901

165,655

Diluted

169,737

166,548

167,901

165,655

OTHER COMPREHENSIVE INCOME (LOSS) NET OF TAX:

Gain (loss) on cash flow hedge

(3,422

)

(381

)

(5,432

)

4,019

OTHER COMPREHENSIVE INCOME (LOSS)

(3,422

)

(381

)

(5,432

)

4,019

COMPREHENSIVE INCOME (LOSS)

$

15,970

$

22,133

$

(17,091

)

$

(15,951

)

SELECTQUOTE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

Six Months Ended December 31,

2023

2022

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss

$

(11,659

)

$

(19,970

)

Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:

Depreciation and amortization

11,887

13,990

Loss on disposal of property, equipment, and software

9

376

Share-based compensation expense

6,997

5,566

Deferred income taxes

(1,182

)

(4,572

)

Amortization of debt issuance costs and debt discount

3,356

3,919

Write-off of debt issuance costs

710

Accrued interest payable in kind

9,020

4,920

Non-cash lease expense

1,528

2,082

Changes in operating assets and liabilities:

Accounts receivable, net

11,975

14,036

Commissions receivable

(113,860

)

(114,701

)

Other assets

(2,075

)

1,578

Accounts payable and accrued expenses

29,206

950

Operating lease liabilities

(2,689

)

(2,460

)

Other liabilities

8,248

18,002

Net cash used in operating activities

(49,239

)

(75,574

)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchases of property and equipment

(2,062

)

(598

)

Proceeds from sales of property and equipment

253

Purchases of software and capitalized software development costs

(3,883

)

(3,870

)

Net cash used in investing activities

(5,692

)

(4,468

)

CASH FLOWS FROM FINANCING ACTIVITIES:

Payments on Term Loans

(16,942

)

(13,375

)

Payments on other debt

(75

)

(83

)

Proceeds from common stock options exercised and employee stock purchase plan

1,078

Payments of tax withholdings related to net share settlement of equity awards

(359

)

(33

)

Payments of debt issuance costs

(10,110

)

Payment of acquisition holdback

(2,335

)

Net cash used in financing activities

(17,376

)

(24,858

)

NET DECREASE IN CASH AND CASH EQUIVALENTS

(72,307

)

(104,900

)

CASH AND CASH EQUIVALENTS—Beginning of period

83,156

140,997

CASH AND CASH EQUIVALENTS—End of period

$

10,849

$

36,097

SELECTQUOTE, INC. AND SUBSIDIARIES

Net Income (Loss) to Adjusted EBITDA Reconciliation

(Unaudited)

Three Months Ended December 31, 2023

(in thousands)

Senior

Healthcare Services

Life

Auto & Home

Corp & Elims

Consolidated

Revenue

$

247,529

$

111,710

$

37,367

$

10,487

$

(1,655

)

$

405,438

Operating expenses

(168,816

)

(108,729

)

(32,798

)

(5,762

)

(21,919

)

(338,024

)

Other income (expense), net

Adjusted EBITDA

$

78,713

$

2,981

$

4,569

$

4,725

$

(23,574

)

$

67,414

Share-based compensation expense

(3,822

)

Transaction costs

(2,400

)

Depreciation and amortization

(5,898

)

Interest expense, net

(24,415

)

Income tax expense

(11,487

)

Net income

$

19,392

Three Months Ended December 31, 2022

(in thousands)

Senior

Healthcare Services

Life

Auto & Home

Corp & Elims

Consolidated

Revenue

$

223,826

$

55,480

$

33,995

$

7,808

$

(1,921

)

$

319,188

Operating expenses

(140,209

)

(64,781

)

(28,152

)

(5,524

)

(16,877

)

(255,543

)

Other income (expense), net

(70

)

(70

)

Adjusted EBITDA

$

83,617

$

(9,301

)

$

5,843

$

2,284

$

(18,868

)

$

63,575

Share-based compensation expense

(2,936

)

Transaction costs

(442

)

Depreciation and amortization

(7,188

)

Loss on disposal of property, equipment, and software

(46

)

Interest expense, net

(21,044

)

Income tax expense

(9,405

)

Net income

$

22,514

Six Months Ended December 31, 2023

(in thousands)

Senior

Healthcare Services

Life

Auto & Home

Corp & Elims

Consolidated

Revenue

$

337,445

$

209,078

$

75,170

$

19,515

$

(3,041

)

$

638,167

Operating expenses

(260,069

)

(203,774

)

(65,362

)

(11,470

)

(41,415

)

(582,090

)

Other income (expense), net

(39

)

(39

)

Adjusted EBITDA

$

77,376

$

5,304

$

9,808

$

8,045

$

(44,495

)

$

56,038

Share-based compensation expense

(6,997

)

Transaction costs

(4,305

)

Depreciation and amortization

(11,887

)

Loss on disposal of property, equipment, and software

(9

)

Interest expense, net

(45,811

)

Income tax benefit

1,312

Net loss

$

(11,659

)

Six Months Ended December 31, 2022

(in thousands)

Senior

Healthcare Services

Life

Auto & Home

Corp & Elims

Consolidated

Revenue

$

301,340

$

98,546

$

70,830

$

14,890

$

(3,934

)

$

481,672

Operating expenses

(221,574

)

(119,635

)

(59,963

)

(10,164

)

(34,322

)

(445,658

)

Other income (expense), net

201

(1

)

(112

)

88

Adjusted EBITDA

$

79,766

$

(21,089

)

$

11,068

$

4,725

$

(38,368

)

$

36,102

Share-based compensation expense

(5,566

)

Transaction costs

(2,570

)

Depreciation and amortization

(13,990

)

Loss on disposal of property, equipment, and software

(371

)

Interest expense, net

(37,780

)

Income tax benefit

4,205

Net loss

$

(19,970

)

SELECTQUOTE, INC. AND SUBSIDIARIES

Net Loss to Adjusted EBITDA Reconciliation

(Unaudited)

Guidance net loss to Adjusted EBITDA reconciliation, year ending June 30, 2024:

(in thousands)

Range

Net loss

$

(45,000

)

$

(22,000

)

Income tax benefit

(8,000

)

(4,000

)

Interest expense, net

97,000

92,000

Depreciation and amortization

24,000

22,000

Share-based compensation expense

15,000

12,000

Non-recurring expenses

7,000

5,000

Adjusted EBITDA

$

90,000

$

105,000



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today